Abbott India Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy to step down
Mumbai: Abbott India has announced that Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy, has tendered her resignation from employment of the Company with effect from the close of business hours of April 15, 2025.
She has resigned to pursue opportunities outside the Company.
Following her resignation, she will also cease to be the Senior Management Personnel of the Company effective the said date, the Company informed in a BSE filing.
Namita joined the Company in October 2021 as Associate Director - New Product Introductions and Therapy Area Strategy. She is a result oriented pharmaceutical professional with an enriching experience of over 25 years in Pharmaceutical and Healthcare business. Prior to joining Abbott, Namita was associated with Sun Pharma as GM Portfolio Management. She has also worked with Wockhardt; Alkem Laboratories; Indoco Remedies; Ipca Labs; Charak Pharma and Lupin Laboratories.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.